Mushroom Polysaccharides: Cardiac Remodeling After Injury

Mushroom Cardiac Protection Mechanisms

2023 Animal Study

Ergothioneine — the antioxidant found almost exclusively in mushrooms — reduced cardiac fibrosis and preserved heart function after acute myocardial infarction in animal research.

Beelman et al., Food Chemistry, 2023

Ergothioneine

mushroom-exclusive antioxidant with documented anti-fibrotic effects in heart attack models

Beta-glucans

mushroom polysaccharides with direct anti-inflammatory effects on cardiovascular tissue, beyond cholesterol reduction

Cordyceps

2024 Phytomedicine review documents ischemia-reperfusion cardiac protection in animal models

Beelman et al., Food Chemistry, 2023

View as image ↗

Most people who survive a heart attack think the hardest part is over. But in the weeks and months that follow, something quieter and more dangerous can be happening inside the heart muscle. The cells that survived start sending distress signals. The tissue around them responds by laying down scar material. The chambers change shape. This chain reaction, the organ restructuring itself in response to damage, is called cardiac remodeling, and it's one of the main pathways through which a survived heart attack eventually becomes heart failure years later.

Mushroom polysaccharides and cardiac remodeling have come together as a research topic mostly in animal models, but the findings are specific enough to be worth understanding. A 2023 study in Food Chemistry found that ergothioneine, an antioxidant found almost exclusively in mushrooms, reduced fibrosis and preserved cardiac function in an acute heart attack animal model.^[1] A 2021 systematic review in the American Journal of Medicine documented multiple mechanisms by which mushroom compounds may act directly on cardiac tissue, separate from the better-known effects on cholesterol that are covered in the mushroom cardiovascular health overview.^[2] The honest framing: this is almost entirely preclinical science. No human trials have tested mushroom compounds specifically for cardiac remodeling prevention. What the animal evidence actually shows, and what it cannot yet establish, is what this article covers.

What Cardiac Remodeling Actually Is (And Why the Heart Attack Is Just the Beginning)

Cardiac remodeling is the structural change the heart undergoes after injury: dead muscle cells are replaced by stiff scar tissue (fibrosis), the surviving cells enlarge and thicken the chamber walls (hypertrophy), and the ventricle shifts from an efficient oval shape to a rounder, less effective form. Over months to years, this process reduces pumping function and can progress to heart failure.

Mushroom polysaccharides like beta-glucans and ergothioneine have been studied for their ability to interfere with the fibrotic and hypertrophic pathways driving this change.

That definition is the critical context for everything that follows. The reason cardiac remodeling matters more than the heart attack itself, in terms of long-term outcomes, is that the acute event kills cells but the remodeling process determines how much of the remaining heart is preserved or degraded over the following years.

Here is what drives remodeling. When heart muscle cells die, the surviving cells and surrounding tissue respond with a series of chemical signals. Some of these signals are protective in the short term, sealing off damaged areas and stabilizing the structure. But in large infarctions, or in hearts that receive inadequate treatment, the signals become self-reinforcing. Inflammatory molecules recruit immune cells. Those immune cells trigger the production of collagen, which forms scar tissue. The scar tissue is stiff and cannot contract, so the remaining healthy muscle has to work harder to compensate. The increased workload triggers the surviving cells to grow larger, thickening the walls. This enlargement uses more oxygen. The now-larger heart with partially scarred walls is less efficient per beat. Over time, the cycle worsens.

The weeks immediately following a cardiac injury are the most active period for fibrotic and hypertrophic signaling. Researchers studying potential interventions, including mushroom-derived compounds, focus on this window precisely because interrupting these signals early could limit the extent of long-term structural degradation.

A 2021 systematic review in the American Journal of Medicine by Tharrey and colleagues surveyed the cardiovascular evidence for mushrooms and concluded that the documented mechanisms include both indirect effects (lipid reduction, blood pressure changes) and direct effects on cardiac tissue, including effects relevant to the remodeling process.^[2] The review was explicit that most of this direct cardiac tissue evidence comes from animal models and observational studies, with limited randomized trial data. That limitation runs through the entire research area.

Ergothioneine After a Heart Attack: What the 2023 Animal Study Found

The most specific cardiac remodeling data for any mushroom compound comes from a study by Beelman and colleagues, published in Food Chemistry in 2023. The researchers tested ergothioneine in an animal model of acute myocardial infarction, a heart attack caused by complete blockage of a coronary artery, and measured what happened to cardiac structure and function in the weeks afterward.^[1]

Ergothioneine is a sulfur-containing amino acid and antioxidant that the human body cannot synthesize on its own. Mushrooms are its primary dietary source by a substantial margin. Meat, legumes, and certain whole grains contain trace amounts, but the concentrations found in fungi — particularly in species like shiitake, oyster, and king trumpet mushrooms — exceed what other common foods provide. This biological fact creates a specific research question: can a compound obtained almost exclusively from mushrooms change what happens inside the damaged heart after an injury?

In the Beelman study, ergothioneine reduced fibrosis in the cardiac tissue after infarction, meaning less scar material accumulated in the damaged area.^[1] It also preserved cardiac function during the post-infarction period. The proposed mechanism involves ergothioneine acting as a scavenger of reactive molecules produced by damaged and dying cells, neutralizing the chemical signals that would otherwise drive collagen deposition in the injured tissue. By reducing this oxidative burden in the post-injury environment, the scar-formation cascade is less strongly triggered.

The significance of this study relative to other mushroom cardiovascular research is its specificity. Most of the literature on mushrooms and heart health focuses on cholesterol profiles, blood pressure, or general antioxidant markers in blood. The Beelman study targeted the post-injury structural change directly, which is a more clinically targeted question. It is not asking whether mushrooms are vaguely good for the cardiovascular system; it is asking whether a specific compound disrupts a specific pathological process at a specific time point.

This is a preclinical finding. It establishes that the biological pathway exists and that ergothioneine can interact with it in the animal model tested. It does not establish that eating mushrooms after a heart attack would produce the same effect in people. That clinical question has not been tested.

The broader evidence base for ergothioneine and cardiovascular disease, including population data on mushroom intake and cardiovascular events, is covered in the ergothioneine and cardiovascular disease article.

Beta-Glucans and Heart Tissue: More Than a Cholesterol Fix

Beta-glucans are the long-chain carbohydrates that form the structural backbone of fungal cell walls. They are the best-studied cardiovascular compound in mushrooms, primarily known for their ability to lower LDL cholesterol. But the research on beta-glucans and heart tissue extends beyond the cholesterol mechanism.

A 2018 review by Angeloni and colleagues in the International Journal of Molecular Sciences examined beta-glucan cardiovascular mechanisms comprehensively and found that anti-inflammatory and antioxidant effects on cardiovascular tissue are documented independently of the cholesterol pathway.^[4]

Here is how the cholesterol mechanism works. In the gut, beta-glucans form a viscous gel that binds bile acids and prevents them from being reabsorbed. The liver, needing to replace the excreted bile acids, draws on circulating cholesterol to make new ones. The result is lower LDL. This is the mechanism behind the FDA-authorized health claim for oat beta-glucans and cardiovascular disease. Mushroom beta-glucans work through similar chemistry in the digestive tract.

The non-cholesterol mechanisms are less well known and more relevant to the cardiac remodeling question. Beta-glucans interact with surface receptors on immune cells, including a receptor called Dectin-1 that recognizes fungal cell wall components. This interaction can trigger anti-inflammatory responses in those immune cells. When those cells are present in or near cardiac tissue, the anti-inflammatory signaling may reduce the inflammatory burden driving fibrosis and hypertrophy.^[4] Angeloni and colleagues also documented direct antioxidant activity in cardiovascular tissue, separate from both the cholesterol and immune pathways.

The connection to cardiac remodeling is inferential rather than directly tested. The fibrotic signaling in post-injury cardiac tissue is driven partly by inflammation. If beta-glucans suppress that inflammation through the immune cell pathway, less fibrosis might result. This is mechanistically plausible based on what Angeloni documented, but a study specifically testing beta-glucans in a cardiac remodeling model has not established the link. The broader overview of how beta-glucans and other mushroom polysaccharides contribute to cardiac defense is covered in mushrooms and cardiac protection mechanisms.

Cordyceps and Ischemia-Reperfusion: Protecting the Heart When Blood Returns

There is a type of cardiac injury that happens not during the blockage, but when blood flow is restored. When oxygen-deprived muscle suddenly receives blood again, the returning oxygen triggers a burst of chemical activity that can damage cells that survived the original blockage. This is called ischemia-reperfusion injury, and it contributes to the total cardiac damage sustained during and after a heart attack.

Cordyceps mushroom compounds have been studied specifically for this mechanism. A comprehensive 2024 review in Phytomedicine examined Cordyceps effects on ischemic cardiovascular and cerebrovascular injury and documented multiple pathways through which Cordyceps extracts reduced tissue damage in animal ischemia-reperfusion models.^[3]

The biology of ischemia-reperfusion injury is this: oxygen deprivation forces cells into anaerobic metabolism, which builds up acidic byproducts and primes the cellular machinery for a damaging chemical reaction. When blood flow returns and oxygen arrives, a burst of free radicals is produced — reactive molecules that attack cell membranes, mitochondria, and DNA. The cells that survive the blockage can be killed by the reperfusion rather than the ischemia. Cordyceps compounds appear to buffer this oxidative burst, reducing the number of cells killed when blood flow is restored.

This mechanism is distinct from the fibrosis and hypertrophy pathways discussed above. It operates during the acute injury phase, in the hours surrounding the event, rather than the weeks-long remodeling period that follows. But limiting acute injury has a downstream consequence for remodeling: the extent of the initial damage determines the scale of the structural response. Less cell death at the moment of reperfusion may mean less scar-tissue formation over the subsequent weeks.

The 2024 Phytomedicine review covered both cardiovascular and cerebrovascular ischemia findings, showing that Cordyceps mechanisms extend beyond the heart to other tissues. All of the reviewed evidence was from animal models and in vitro work. The complete Cordyceps cardiac evidence base, including the acute myocardial protection data and the ischemia-reperfusion research, is covered in Cordyceps and myocardial ischemia.

The Evidence Gap Nobody Discusses: All of This Is Preclinical

The honest summary of where mushroom polysaccharides and cardiac remodeling research stands is this: the animal data is specific and mechanistically grounded, but no human trial has tested whether these compounds actually slow cardiac remodeling in people after heart injury.

The Tharrey systematic review, published in the American Journal of Medicine in 2021, remains the most authoritative survey of the cardiovascular evidence base for mushrooms.^[2] Tharrey and colleagues reviewed observational cohort studies, animal experiments, and randomized controlled trials. Their conclusion: most cardiovascular evidence for mushrooms comes from observational data and animal models, with limited randomized trial data. The clinical trial evidence that does exist focuses on indirect benefits, primarily cholesterol and blood pressure reduction, not on cardiac tissue remodeling specifically.

Why the gap? Cardiac remodeling trials are difficult to design and execute. They require participants who have recently experienced a heart attack. They need imaging technology, typically echocardiography or cardiac MRI, to measure changes in cardiac structure over a follow-up period of months to years. They need to control for the many medications, including ACE inhibitors, beta blockers, and statins, that people recovering from heart attacks typically take, all of which also affect remodeling. The sample sizes required to detect differences against that background are substantial. Animal models allow researchers to establish whether a mechanism exists before investing in that infrastructure, and the current evidence base for mushroom compounds is at that proof-of-concept stage.

This does not mean the preclinical findings are trivial. The Beelman ergothioneine study is exactly the type of evidence that would be used to justify designing a human trial. The anti-inflammatory mechanism documented by Angeloni for beta-glucans is biologically coherent. The Cordyceps ischemia-reperfusion data across multiple independent animal models represents convergent evidence from different research groups. These are not weak or isolated signals. Translating animal findings to human outcomes has a well-documented failure rate in medicine, and cardiac pharmacology in particular has seen many promising animal-model findings that did not hold up in clinical trials. The research is worth knowing about; it is not yet evidence of a clinical benefit in people.

Other mushroom species have been studied for cardiac protection through different mechanisms. Reishi's specific evidence in heart failure animal models is covered in reishi and heart failure research. Taiwan's Antrodia camphorata, which has a distinct research literature on cardiac protection, is covered in Antrodia camphorata and heart protection. For the role of clot-dissolving mechanisms in post-injury cardiac recovery, the fibrinolytic enzymes in mushrooms article covers a related protective pathway.

The Bottom Line

Mushroom compounds, particularly ergothioneine and beta-glucans, have been studied for their effects on cardiac remodeling in animal models. The 2023 Beelman study in Food Chemistry is the most specific evidence to date, showing ergothioneine reduced cardiac fibrosis and preserved function in a heart attack model. The 2021 Tharrey systematic review in the American Journal of Medicine confirms that mushroom cardiovascular mechanisms extend beyond cholesterol effects, but almost all direct cardiac tissue evidence remains preclinical. No human trial has tested whether any mushroom compound slows cardiac remodeling in people after heart injury.

Frequently Asked Questions

What is cardiac remodeling and why does it happen?

Cardiac remodeling is the structural change the heart undergoes after injury: dead muscle cells are replaced by scar tissue (fibrosis), surviving cells enlarge and thicken the chamber walls (hypertrophy), and the ventricle shifts to a rounder, less efficient form. It happens because the heart's damage-response system, which is useful in the short term for sealing injured areas, becomes self-reinforcing at larger scales. Inflammatory signals drive collagen deposition, which forms stiff scar tissue, which increases mechanical stress on surviving cells, which triggers further hypertrophy. Over months to years, this progression can lead to heart failure.

Can beta-glucan prevent heart failure?

No beta-glucan human trial has directly tested prevention of heart failure or cardiac remodeling. What's documented is that beta-glucans reduce LDL cholesterol through bile acid binding in the gut, and have anti-inflammatory and antioxidant effects on cardiovascular tissue through immune cell receptors, per Angeloni et al. in the International Journal of Molecular Sciences (2018). Whether these mechanisms are sufficient to modify heart failure development in people has not been tested in a clinical trial.

Do mushroom compounds help after a heart attack?

In animal models, specific mushroom compounds have shown effects relevant to post-heart-attack recovery. Ergothioneine reduced cardiac fibrosis and preserved function after acute myocardial infarction in a 2023 animal study by Beelman and colleagues. Cordyceps compounds reduced ischemia-reperfusion injury, the damage that occurs when blood flow returns after a blockage, in animal models reviewed in 2024. In people, no trials have tested mushroom compounds specifically for post-heart-attack cardiac remodeling. The human evidence for mushrooms and cardiovascular health focuses mainly on cholesterol and blood pressure, not post-MI structural recovery.

What is anti-fibrotic therapy for the heart?

Anti-fibrotic therapy aims to reduce the accumulation of scar tissue in heart muscle after injury, which is one of the main drivers of declining heart function over time. In clinical practice, drugs including ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists have anti-fibrotic effects as part of their mechanism in heart failure treatment. Mushroom compounds like ergothioneine have shown anti-fibrotic effects in cardiac animal models, but have not been evaluated in anti-fibrotic clinical trials or compared directly against approved medications.

Can ergothioneine protect heart muscle?

In animal research, ergothioneine reduced cardiac fibrosis and preserved heart function after acute myocardial infarction, according to Beelman et al. in Food Chemistry (2023). Ergothioneine is found in much higher concentrations in mushrooms than in any other common food; the human body cannot make it. Its proposed mechanism is neutralizing the reactive molecules that trigger scar-tissue formation in damaged cardiac tissue. No human trial has tested ergothioneine supplementation or mushroom consumption specifically for post-MI cardiac protection.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.